Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) insider Najat Khan sold 124,403 shares of the firm's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $4.41, for a total transaction of $548,617.23. Following the sale, the insider owned 611,135 shares in the company, valued

Wall Street is ending 2026 on a generally positive note, with the benchmark S&P 500 Index set to finish the year at a 17% return rate. All eyes are now on technology titans like Nvidia, Microsoft, Alphabet, and Amazon, which have dominated the headlines in 2025, and for good reason.

The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.

Cathie Wood's ARK Invest once again trimmed its stake in Tesla (TSLA) while increasing exposure to crypto-related stocks, according to a Thursday filing with th

Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, derisking the lead program ahead of pivotal studies. RXRX's $2.44bn market cap is justified by FAP opportunity, robust partnerships, and over $100m in milestone payments expected by end-2026.

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However, here's a reality check: RXRX remains down by 35% year-to-date and is trading below $5.

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors purchased 37,151 call options on the company. This is an increase of approximately 42% compared to the average daily volume of 26,190 call options. Insider Activity at Recursion Pharmaceuticals In related news, Director Blake

Cathie Wood-led Ark Invest executed several significant trades on Wednesday, with notable activity in Bitmine Immersion Technologies Inc (ASE: BMNR), Coinbase Global Inc (NASDAQ:

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold.

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing.